NL-OMON50929RecruitingNot Applicable
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations - Luxturna® Follow Up
Oogziekenhuis Rotterdam0 sites20 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational non invasive
Eligibility Criteria
- Ages
- 2 to 99 (—)
Inclusion Criteria
- •Scheduled to receive treatment with Luxturna®
- •Informed consent
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Phase 1
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsEUCTR2021-000265-33-NLThe Rotterdam Eye Hospital20
Not yet recruiting
Not Applicable
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations (IRDs).NL-OMON22976The Rotterdam Eye Hospital20
Completed
Not Applicable
Safety and preliminary protective efficacy of genetically attenuated Pf*mei2 (GA2) malaria parasites in healthy Dutch volunteersparasitaire ziekte10037072MalariaNL-OMON51062eids Universitair Medisch Centrum51
Recruiting
Not Applicable
Evaluation Study for its Clinical Utility of Gene Prognostic Signature MammaPrint for Early-Breast CancerBreast CancerJPRN-UMIN000002834Department of Breast and Endocrine Surjery, Juntendo University School of Medicine50
Not yet recruiting
Phase 3
Effect of tranexamic acid and aprotinin in absolute blood loss in pediatric neurosurgeryIRCT20200705048023N1Tehran University of Medical Sciences90